Compare · GILD vs IAM
GILD vs IAM
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Iambic Therapeutics Inc. (IAM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and IAM operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $206.55B, about 305.6x IAM ($675.9M).
- GILD has been more active in the news (22 items in the past 4 weeks vs 10 for IAM).
- GILD has more recent analyst coverage (25 ratings vs 4 for IAM).
- Company
- Gilead Sciences Inc.
- Iambic Therapeutics Inc.
- Price
- -
- -
- Market cap
- $206.55B
- $675.9M
- 1M return
- +8.45%
- -
- 1Y return
- +33.25%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2026
- News (4w)
- 22
- 10
- Recent ratings
- 25
- 4
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Iambic Therapeutics Inc.
Iambic's mission is to make better technology for better medicines. By utilizing molecular superintelligence - integrating proprietary AI with automated, scalable chemistry and biology experimentation - our platform is designed to address the totality of drug discovery and development. We believe the utility of our platform is demonstrated by the discovery of IAM1363, a novel drug candidate advanced to clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine.
Latest GILD
- Chief Comm & Corp Aff Officer Johanna Mercier exercised 25,000 shares at a strike of $72.34 and sold $4,775,527 worth of shares (28,000 units at $170.55) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 110,684 units (SEC Form 4)
- Chief Financial Officer Andrew D Dickinson sold $514,410 worth of shares (3,000 units at $171.47) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 158,096 units (SEC Form 4)
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- Director Kramer Kelly A. exercised 10,376 shares at a strike of $66.92 and sold $1,761,437 worth of shares (10,376 units at $169.76) as part of a pre-agreed trading plan (SEC Form 4)
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M sold $557,810 worth of shares (3,399 units at $164.11) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 5,360 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Chairman & CEO O'Day Daniel Patrick exercised 112,429 shares at a strike of $72.34 and sold $19,693,439 worth of shares (112,429 units at $175.16) as part of a pre-agreed trading plan (SEC Form 4)
- New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Latest IAM
- SEC Form 10-Q filed by Iambic Therapeutics Inc.
- Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
- Iambic Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Iambic Provides Business Updates and Third Quarter 2026 Financial Results
- Jefferies initiated coverage on Iambic Therapeutics with a new price target
- SEC Form SCHEDULE 13G filed by Iambic Therapeutics Inc.
- Iambic to participate in Jefferies Global Healthcare Conference
- Analyst initiated coverage on Iambic Therapeutics with a new price target
- Citigroup initiated coverage on Iambic Therapeutics with a new price target
- BofA Securities initiated coverage on Iambic Therapeutics with a new price target